^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Solid Tumor

    Related cancers:
    1d
    JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P2 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    JS111
    1d
    Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment (clinicaltrials.gov)
    P2, N=27, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial primary completion date
    |
    Focus V (anlotinib) • Kaitanni (cadonilimab)
    1d
    Pathogenic Variants in Genes Associated With Lung Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=332, Recruiting, Oscar Gerardo Arrieta Rodríguez | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    MET exon 14 mutation
    1d
    Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors (clinicaltrials.gov)
    P1, N=40, Recruiting, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
    New P1 trial
    1d
    OVHIPEC-2: Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (clinicaltrials.gov)
    P3, N=538, Active, not recruiting, The Netherlands Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Dec 2028 | Trial primary completion date: Apr 2025 --> Apr 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cisplatin
    1d
    Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence (clinicaltrials.gov)
    P2, N=100, Recruiting, University of Arkansas | Trial completion date: Feb 2029 --> Jul 2031 | Trial primary completion date: Feb 2029 --> Jul 2031
    Trial completion date • Trial primary completion date
    1d
    177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: May 2026 --> Sep 2026
    Trial completion date
    |
    177Lu-rosopatamab tetraxetan (TLX591)
    1d
    HORIZON 2: A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=11, Active, not recruiting, Hoffmann-La Roche | Phase classification: P3 --> P1/2 | Trial completion date: Mar 2033 --> Aug 2026 | Trial primary completion date: Jun 2028 --> Aug 2026
    Phase classification • Trial completion date • Trial primary completion date
    |
    ALK fusion
    |
    cisplatin • carboplatin • Alecensa (alectinib) • pemetrexed
    1d
    VA STARPORT: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (clinicaltrials.gov)
    P2/3, N=464, Recruiting, VA Office of Research and Development | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    1d
    Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment (clinicaltrials.gov)
    P3, N=400, Recruiting, Boehringer Ingelheim
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HER-2 mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Hernexeos (zongertinib)
    1d
    Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial (clinicaltrials.gov)
    P3, N=280, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting
    Enrollment closed
    1d
    HARMONY: Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (clinicaltrials.gov)
    P2, N=0, Withdrawn, Qian Qin | Trial completion date: Apr 2028 --> Jan 2029 | Trial primary completion date: Apr 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD54L (DNA Repair And Recombination Protein RAD54)
    |
    docetaxel • abiraterone acetate • Akeega (abiraterone/niraparib)